Eversept Partners, LP Autolus Therapeutics PLC Transaction History

Eversept Partners, LP

  • $993 Million
  • Q2 2025

A detailed history of Eversept Partners, LP transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Eversept Partners, LP holds 610,231 shares of AUTL stock, worth $1 Million. This represents 0.14% of its overall portfolio holdings.

Number of Shares
610,231
Previous 343,947 77.42%
Holding current value
$1 Million
Previous $533,000 160.98%
% of portfolio
0.14%
Previous 0.06%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 14, 2025
BUY
$1.14 - $2.4 $303,563 - $639,081
266,284 Added 77.42%
610,231 $1.39 Million
Q1 2025

May 15, 2025
BUY
$1.55 - $2.68 $379,830 - $656,739
245,052 Added 247.79%
343,947 $533,000
Q4 2024

Feb 14, 2025
SELL
$2.18 - $4.8 $670,705 - $1.48 Million
-307,663 Reduced 75.68%
98,895 $232,000
Q3 2024

Nov 14, 2024
SELL
$3.38 - $4.69 $690,682 - $958,373
-204,344 Reduced 33.45%
406,558 $1.48 Million
Q2 2024

Aug 14, 2024
BUY
$3.33 - $5.68 $2.03 Million - $3.47 Million
610,902 New
610,902 $2.13 Million
Q2 2022

Aug 15, 2022
SELL
$2.04 - $4.68 $757,941 - $1.74 Million
-371,540 Closed
0 $0
Q1 2022

Nov 08, 2023
BUY
$3.52 - $5.46 $1.31 Million - $2.03 Million
371,540 New
371,540 $1.55 Million
Q1 2022

May 16, 2022
SELL
$3.52 - $5.46 $105,600 - $163,800
-30,000 Reduced 7.47%
371,540 $1.55 Million
Q4 2021

Nov 08, 2023
BUY
$5.1 - $7.0 $17,676 - $24,262
3,466 Added 0.87%
401,540 $2.08 Million
Q4 2021

Feb 14, 2022
BUY
$5.1 - $7.0 $17,676 - $24,262
3,466 Added 0.87%
401,540 $2.08 Million
Q3 2021

Nov 08, 2023
SELL
$5.32 - $7.37 $399,000 - $552,750
-75,000 Reduced 15.85%
398,074 $2.61 Million
Q3 2021

Nov 15, 2021
SELL
$5.32 - $7.37 $399,000 - $552,750
-75,000 Reduced 15.85%
398,074 $2.61 Million
Q2 2021

Nov 08, 2023
BUY
$4.78 - $7.96 $1.52 Million - $2.53 Million
318,093 Added 205.25%
473,074 $3.14 Million
Q2 2021

Aug 16, 2021
BUY
$4.78 - $7.96 $2.26 Million - $3.77 Million
473,074 New
473,074 $3.14 Million
Q1 2021

May 13, 2021
SELL
$5.49 - $9.36 $850,845 - $1.45 Million
-154,981 Closed
0 $0
Q4 2020

Nov 08, 2023
BUY
$8.13 - $12.79 $1.26 Million - $1.98 Million
154,981 New
154,981 $1.39 Million
Q4 2020

Feb 16, 2021
SELL
$8.13 - $12.79 $840,471 - $1.32 Million
-103,379 Reduced 40.01%
154,981 $1.39 Million
Q2 2020

Nov 08, 2023
BUY
$5.38 - $16.14 $260,106 - $780,320
48,347 Added 23.02%
258,360 $4.14 Million
Q2 2020

Aug 13, 2020
BUY
$5.38 - $16.14 $260,106 - $780,320
48,347 Added 23.02%
258,360 $4.14 Million
Q1 2020

Nov 08, 2023
BUY
$4.2 - $13.0 $882,054 - $2.73 Million
210,013 New
210,013 $1.26 Million
Q1 2020

May 13, 2020
BUY
$4.2 - $13.0 $882,054 - $2.73 Million
210,013 New
210,013 $1.26 Million

Others Institutions Holding AUTL

# of Institutions
100
Shares Held
164M
Call Options Held
0
Put Options Held
39.3K
View Full List

About Autolus Therapeutics plc

AUTL Quotes by TradingView
  • Ticker AUTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,909,800
  • Market Cap $149M
  • Description
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...
More about AUTL
Track This Portfolio

Track Eversept Partners, LP Portfolio

Follow Eversept Partners, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eversept Partners, LP, based on Form 13F filings with the SEC.

News

Stay updated on Eversept Partners, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email